Findings from the “Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level” study were published in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP trial, found that Control-IQ+ automated insulin delivery technology proved beneficial for adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels.
San Diego-based Tandem — one of the largest diabetes tech companies in the world — said the analysis looked at 254 of the 319 participants in the 2IQP trial. Researchers categorized participants, all of whom had type 2 diabetes and were using a t:slim X2 insulin pump with Control-IQ+ AID technology, into a ‘high C-peptide’ group (N=195) and a ‘low C-peptide’ group (N=59) based on CMS criteria.
Read more about Tandem and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Participants in the AID group saw a mean HbA1c decrease of 0.8% from baseline. That came in significantly greater than the control group. The improvement proved the same between the high and low C-peptide groups. Tandem said this demonstrates the benefit of AID regardless of C-peptide levels.
Currently, CMS criteria requires a low C-peptide level for insulin pump coverage, according to the company. This excludes many with type 2 diabetes from obtaining an AID system, even if they benefitted from the technology prior to Medicare.
“The 2IQP trial demonstrated that AID provides benefits to adults with insulin-treated type 2 diabetes across a range of demographics and treatment regimens, comparable to the outcomes seen in type 1 diabetes,” said Irl B. Hirsch, MD, from the University of Washington School of Medicine and lead author of the manuscript. “These new analyses show that AID is effective regardless of C-peptide levels, indicating that a low C-peptide threshold should not be required for therapy.”
